Guidelines for the management of myeloproliferative neoplasms

Chul Won Choi, Soo Mee Bang, Seongsoo Jang, Chul Won Jung, Hee Jin Kim, Ho Young Kim, Soo Jeong Kim, Yeo Kyeoung Kim, Jinny Park, Jong Ho Won

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Polycythemia vera, essential thrombocythemia, and primary myelofibrosis are collectively known as ‘Philadelphia-negative classical myeloproliferative neoplasms (MPNs).’ The discovery of new genetic aberrations such as Janus kinase 2 (JAK2) have enhanced our understanding of the pathophysiology of MPNs. Currently, the JAK2 mutation is not only a standard criterion for diagnosis but is also a new target for drug development. The JAK1/2 inhibitor, ruxolitinib, was the first JAK inhibitor approved for patients with intermediate- to high-risk myelofibrosis and its effects in improving symptoms and survival benefits were demonstrated by randomized controlled trials. In 2011, the Korean Society of Hematology MPN Working Party devised diagnostic and therapeutic guidelines for Korean MPN patients. Subsequently, other genetic mutations have been discovered and many kinds of new drugs are now under clinical investigation. In view of recent developments, we have revised the guidelines for the diagnosis and management of MPN based on published evidence and the experiences of the expert panel. Here we describe the epidemiology, new genetic mutations, and novel therapeutic options as well as diagnostic criteria and standard treatment strategies for MPN patients in Korea.

Original languageEnglish
Pages (from-to)771-788
Number of pages18
JournalKorean Journal of Internal Medicine
Volume30
Issue number6
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Guidelines
Janus Kinase 2
Neoplasms
Primary Myelofibrosis
Mutation
Essential Thrombocythemia
Polycythemia Vera
Molecular Epidemiology
Hematology
Korea
Pharmaceutical Preparations
Therapeutics
Randomized Controlled Trials
Survival

Keywords

  • Essential
  • Polycythemia vera
  • Practice guideline
  • Primary myelofibrosis
  • Thrombocythemia

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Choi, C. W., Bang, S. M., Jang, S., Jung, C. W., Kim, H. J., Kim, H. Y., ... Won, J. H. (2015). Guidelines for the management of myeloproliferative neoplasms. Korean Journal of Internal Medicine, 30(6), 771-788. https://doi.org/10.3904/kjim.2015.30.6.771

Guidelines for the management of myeloproliferative neoplasms. / Choi, Chul Won; Bang, Soo Mee; Jang, Seongsoo; Jung, Chul Won; Kim, Hee Jin; Kim, Ho Young; Kim, Soo Jeong; Kim, Yeo Kyeoung; Park, Jinny; Won, Jong Ho.

In: Korean Journal of Internal Medicine, Vol. 30, No. 6, 01.01.2015, p. 771-788.

Research output: Contribution to journalReview article

Choi, CW, Bang, SM, Jang, S, Jung, CW, Kim, HJ, Kim, HY, Kim, SJ, Kim, YK, Park, J & Won, JH 2015, 'Guidelines for the management of myeloproliferative neoplasms', Korean Journal of Internal Medicine, vol. 30, no. 6, pp. 771-788. https://doi.org/10.3904/kjim.2015.30.6.771
Choi, Chul Won ; Bang, Soo Mee ; Jang, Seongsoo ; Jung, Chul Won ; Kim, Hee Jin ; Kim, Ho Young ; Kim, Soo Jeong ; Kim, Yeo Kyeoung ; Park, Jinny ; Won, Jong Ho. / Guidelines for the management of myeloproliferative neoplasms. In: Korean Journal of Internal Medicine. 2015 ; Vol. 30, No. 6. pp. 771-788.
@article{eca62e3d78e54653b982395052a2b1e6,
title = "Guidelines for the management of myeloproliferative neoplasms",
abstract = "Polycythemia vera, essential thrombocythemia, and primary myelofibrosis are collectively known as ‘Philadelphia-negative classical myeloproliferative neoplasms (MPNs).’ The discovery of new genetic aberrations such as Janus kinase 2 (JAK2) have enhanced our understanding of the pathophysiology of MPNs. Currently, the JAK2 mutation is not only a standard criterion for diagnosis but is also a new target for drug development. The JAK1/2 inhibitor, ruxolitinib, was the first JAK inhibitor approved for patients with intermediate- to high-risk myelofibrosis and its effects in improving symptoms and survival benefits were demonstrated by randomized controlled trials. In 2011, the Korean Society of Hematology MPN Working Party devised diagnostic and therapeutic guidelines for Korean MPN patients. Subsequently, other genetic mutations have been discovered and many kinds of new drugs are now under clinical investigation. In view of recent developments, we have revised the guidelines for the diagnosis and management of MPN based on published evidence and the experiences of the expert panel. Here we describe the epidemiology, new genetic mutations, and novel therapeutic options as well as diagnostic criteria and standard treatment strategies for MPN patients in Korea.",
keywords = "Essential, Polycythemia vera, Practice guideline, Primary myelofibrosis, Thrombocythemia",
author = "Choi, {Chul Won} and Bang, {Soo Mee} and Seongsoo Jang and Jung, {Chul Won} and Kim, {Hee Jin} and Kim, {Ho Young} and Kim, {Soo Jeong} and Kim, {Yeo Kyeoung} and Jinny Park and Won, {Jong Ho}",
year = "2015",
month = "1",
day = "1",
doi = "10.3904/kjim.2015.30.6.771",
language = "English",
volume = "30",
pages = "771--788",
journal = "Korean Journal of Internal Medicine",
issn = "0494-4712",
publisher = "Korean Association of Internal Medicine",
number = "6",

}

TY - JOUR

T1 - Guidelines for the management of myeloproliferative neoplasms

AU - Choi, Chul Won

AU - Bang, Soo Mee

AU - Jang, Seongsoo

AU - Jung, Chul Won

AU - Kim, Hee Jin

AU - Kim, Ho Young

AU - Kim, Soo Jeong

AU - Kim, Yeo Kyeoung

AU - Park, Jinny

AU - Won, Jong Ho

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Polycythemia vera, essential thrombocythemia, and primary myelofibrosis are collectively known as ‘Philadelphia-negative classical myeloproliferative neoplasms (MPNs).’ The discovery of new genetic aberrations such as Janus kinase 2 (JAK2) have enhanced our understanding of the pathophysiology of MPNs. Currently, the JAK2 mutation is not only a standard criterion for diagnosis but is also a new target for drug development. The JAK1/2 inhibitor, ruxolitinib, was the first JAK inhibitor approved for patients with intermediate- to high-risk myelofibrosis and its effects in improving symptoms and survival benefits were demonstrated by randomized controlled trials. In 2011, the Korean Society of Hematology MPN Working Party devised diagnostic and therapeutic guidelines for Korean MPN patients. Subsequently, other genetic mutations have been discovered and many kinds of new drugs are now under clinical investigation. In view of recent developments, we have revised the guidelines for the diagnosis and management of MPN based on published evidence and the experiences of the expert panel. Here we describe the epidemiology, new genetic mutations, and novel therapeutic options as well as diagnostic criteria and standard treatment strategies for MPN patients in Korea.

AB - Polycythemia vera, essential thrombocythemia, and primary myelofibrosis are collectively known as ‘Philadelphia-negative classical myeloproliferative neoplasms (MPNs).’ The discovery of new genetic aberrations such as Janus kinase 2 (JAK2) have enhanced our understanding of the pathophysiology of MPNs. Currently, the JAK2 mutation is not only a standard criterion for diagnosis but is also a new target for drug development. The JAK1/2 inhibitor, ruxolitinib, was the first JAK inhibitor approved for patients with intermediate- to high-risk myelofibrosis and its effects in improving symptoms and survival benefits were demonstrated by randomized controlled trials. In 2011, the Korean Society of Hematology MPN Working Party devised diagnostic and therapeutic guidelines for Korean MPN patients. Subsequently, other genetic mutations have been discovered and many kinds of new drugs are now under clinical investigation. In view of recent developments, we have revised the guidelines for the diagnosis and management of MPN based on published evidence and the experiences of the expert panel. Here we describe the epidemiology, new genetic mutations, and novel therapeutic options as well as diagnostic criteria and standard treatment strategies for MPN patients in Korea.

KW - Essential

KW - Polycythemia vera

KW - Practice guideline

KW - Primary myelofibrosis

KW - Thrombocythemia

UR - http://www.scopus.com/inward/record.url?scp=84947075911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947075911&partnerID=8YFLogxK

U2 - 10.3904/kjim.2015.30.6.771

DO - 10.3904/kjim.2015.30.6.771

M3 - Review article

VL - 30

SP - 771

EP - 788

JO - Korean Journal of Internal Medicine

JF - Korean Journal of Internal Medicine

SN - 0494-4712

IS - 6

ER -